menu
What is Atopic Dermatitis?
What is Atopic Dermatitis?
Atopic Dermatitis

Atopic eczema causes the skin to become itchy, dry, cracked and sore. Some people only have small patches of dry skin, but others may experience widespread inflamed skin all over the body. Inflamed skin can become red on lighter skin, and darker brown, purple or grey on darker skin.

This can also be more difficult to see on darker skin. People with atopic eczema usually have periods when symptoms are less noticeable, as well as periods when symptoms become more severe (flare-ups).

According to the National Eczema Association 2020: o Itch is the most burdensome symptom of AD, followed by skin redness and dryness. A recent study of adults with moderate to severe AD found that 70.5% reported severe, unbearable itch in the past two weeks, 85.8% reported daily itch, and 62.8% reported itching at least 12 hours per day.

Skin pain is a newly appreciated symptom of AD, with 61% of affected adults reporting pain, 33% experienced pain at least once per week, and 5.2% had pain daily.

Also, read Atopic Dermatitis Market Share

More than 55% of adults with moderate-to-severe AD report inadequate disease control.

There is currently no specific test for AD, and no single symptom or feature can be used to identify the disease. Each patient has a unique combination of symptoms and a rash appearance. Diagnosis of AD is based on the history and physical examination of the patient. In uncertain cases, a skin biopsy may be taken for a histopathological diagnosis of dermatitis.

Currently, there is no cure for AD; however, it can be effectively managed with current treatment options. The pattern of the disease and its severity determine the kind of treatment the patient ought to receive. Treatment options include topical treatments like emollients, topical corticosteroids (TCS), antibiotics, topical calcineurin inhibitors (TCIs), and systemic treatment such as immunosuppressant, corticosteroids, and phototherapy. Drugs such as Eucrisa (Crisaborole), Dupixent (Dupilumab), Corectim ointment, and Olumiant (baricitinib) are approved for AD

Original Source:- Atopic Dermatitis Market Size